<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Vertex Pharmaceuticals Incorporated — News on 6ix</title>
    <link>https://6ix.com/company/vertex-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Vertex Pharmaceuticals Incorporated on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 21 May 2026 16:56:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/vertex-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d3d178dffbe2df120b82.webp</url>
      <title>Vertex Pharmaceuticals Incorporated</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-new-drug-submission-for-suzetrigine-has-been-accepted-for-review-by-health-canada-for-the-treatment-of-moderate-to-severe-acute-pain-in-adults</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-new-drug-submission-for-suzetrigine-has-been-accepted-for-review-by-health-canada-for-the-treatment-of-moderate-to-severe-acute-pain-in-adults</guid>
      <pubDate>Thu, 21 May 2026 16:56:00 GMT</pubDate>
      <description>Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that Health Canada has accepted for review a New Drug Submission (NDS) for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Suzetrigine is a selective NaV1.8 pain signal inhibitor that represents a new class of oral pain medicine; it is not an opioid or a nonsteroidal anti-inflammatory drug (NSAID). If approved by Health Canada, suzetrigine has the potential to be the first new class of medicine in Canada to treat acu</description>
    </item>
    <item>
      <title>Vertex to Participate in Upcoming May Investor Conferences</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-participate-in-upcoming-may-investor-conferences-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-participate-in-upcoming-may-investor-conferences-1</guid>
      <pubDate>Mon, 11 May 2026 20:00:00 GMT</pubDate>
      <description>BOSTON, May 11, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.</description>
    </item>
    <item>
      <title>Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-casgevyr-reimbursement-agreement-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia-in-germany</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-casgevyr-reimbursement-agreement-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia-in-germany</guid>
      <pubDate>Wed, 06 May 2026 11:01:00 GMT</pubDate>
      <description>BOSTON, May 06, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia.</description>
    </item>
    <item>
      <title>Vertex Reports First Quarter 2026 Financial Results</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-first-quarter-2026-financial-results-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-first-quarter-2026-financial-results-1</guid>
      <pubDate>Mon, 04 May 2026 04:00:00 GMT</pubDate>
      <description>– Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 – – Povetacicept program continues rapid advancement: Completed rolling BLA</description>
    </item>
    <item>
      <title>Vortex Energy Announces Intent to Advance Next Phase of Technical Work at the Robinsons River Salt Project and Engages Lonquist</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vortex-energy-announces-intent-to-advance-next-phase-of-technical-work-at-the-robinsons-river-salt-project-and-engages-lonquist-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vortex-energy-announces-intent-to-advance-next-phase-of-technical-work-at-the-robinsons-river-salt-project-and-engages-lonquist-1</guid>
      <pubDate>Thu, 30 Apr 2026 12:00:00 GMT</pubDate>
      <description>Data integration initiative aimed at refining subsurface model and advancing underground storage potential VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce its intent to advance the next phase of technical work at its Robinsons River Salt Project (the &quot;Project&quot;), located approximately 35 kilometres south of Stephenville, Newfoundland and Labrador, and to announce that it has</description>
    </item>
    <item>
      <title>A Call to Action to Help Fight Kidney Failure in At-Risk Communities:  American Kidney Fund Urges People to be APOL1 Aware</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/a-call-to-action-to-help-fight-kidney-failure-in-at-risk-communities-american-kidney-fund-urges-people-to-be-apol1-aware</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/a-call-to-action-to-help-fight-kidney-failure-in-at-risk-communities-american-kidney-fund-urges-people-to-be-apol1-aware</guid>
      <pubDate>Tue, 28 Apr 2026 13:02:00 GMT</pubDate>
      <description>Newly established AMKD Coalition unites leading voices to address need to heighten awareness of APOL1-mediated kidney disease (AMKD)ROCKVILLE, Md., April 28, 2026 (GLOBE NEWSWIRE) -- Today marks the third annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day, a day established by the American Kidney Fund (AKF) to encourage others to be “APOL1 Aware” by educating communities about this genetic form of rapidly progressing kidney disease. Support for AMKD Awareness Day is provided by Vertex Pha</description>
    </item>
    <item>
      <title>Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercontm-technology-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercontm-technology-1</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
      <description>Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&quot;Halozyme&quot; or the &quot;Company&quot;) today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated (&quot;Vertex&quot;). Under the collaboration, Vertex has licensed Halozyme&apos;s Hypercon™ technology for use in up to three drug targets. Hypercon™ is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reduci</description>
    </item>
    <item>
      <title>Vertex to Announce First Quarter 2026 Financial Results on May 4th</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-announce-first-quarter-2026-financial-results-on-may-4th-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-announce-first-quarter-2026-financial-results-on-may-4th-1</guid>
      <pubDate>Mon, 06 Apr 2026 20:00:00 GMT</pubDate>
      <description>BOSTON, April 06, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the &quot;Vertex Pharmaceuticals First Quarter 2026 Earnings Call.&quot;</description>
    </item>
    <item>
      <title>Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-us-fda-approval-for-label-extensions-of-alyftrekr-and-trikaftar-expanding-availability-of-these-medicines-to-95percent-of-all-people-with-cf-in-the-united-states</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-us-fda-approval-for-label-extensions-of-alyftrekr-and-trikaftar-expanding-availability-of-these-medicines-to-95percent-of-all-people-with-cf-in-the-united-states</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the</description>
    </item>
    <item>
      <title>Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy-18</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy-18</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein</description>
    </item>
    <item>
      <title>Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-present-new-data-on-journavxr-that-demonstrates-effective-pain-management-following-aesthetic-and-reconstructive-procedures-3</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-present-new-data-on-journavxr-that-demonstrates-effective-pain-management-following-aesthetic-and-reconstructive-procedures-3</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral</description>
    </item>
    <item>
      <title>Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer-3</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer-3</guid>
      <pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
      <description>Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somara</description>
    </item>
    <item>
      <title>Vortex Energy Announces Postponement of AGM</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vortex-energy-announces-postponement-of-agm-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vortex-energy-announces-postponement-of-agm-1</guid>
      <pubDate>Wed, 18 Feb 2026 22:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that, due to the absence of quorum at its February 13, 2026, Annual General Meeting (AGM), the holding of the AGM has been postponed. The Company will issue a news release once a new date and other details regarding the AGM have been determined. About Vortex Energy Corp. Vortex Energy Corp. is an exploration stage company engaged principally</description>
    </item>
    <item>
      <title>Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-participate-in-td-cowen-46th-annual-health-care-conference-on-march-3</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-participate-in-td-cowen-46th-annual-health-care-conference-on-march-3</guid>
      <pubDate>Tue, 17 Feb 2026 21:00:00 GMT</pubDate>
      <description>BOSTON, February 17, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET.</description>
    </item>
    <item>
      <title>Vertex Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 12 Feb 2026 21:01:00 GMT</pubDate>
      <description>BOSTON, February 12, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance.</description>
    </item>
    <item>
      <title>Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/jupiter-endovascular-announces-completion-of-enrollment-in-spirare-ii-pivotal-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/jupiter-endovascular-announces-completion-of-enrollment-in-spirare-ii-pivotal-trial</guid>
      <pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
      <description>MENLO PARK, Calif., February 04, 2026--Jupiter Endovascular completes enrollment in a pivotal trial of its Vertex system with Transforming Fixation technology for pulmonary embolectomy.</description>
    </item>
    <item>
      <title>WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),</description>
    </item>
    <item>
      <title>Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/satellos-appoints-antoinette-paone-as-chief-development-officer-and-head-of-regulatory-affairs-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/satellos-appoints-antoinette-paone-as-chief-development-officer-and-head-of-regulatory-affairs-1</guid>
      <pubDate>Thu, 29 Jan 2026 12:00:00 GMT</pubDate>
      <description>TORONTO, January 29, 2026--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (&quot;Satellos&quot; or the &quot;Company&quot;), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer (&quot;CDO&quot;) and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at</description>
    </item>
    <item>
      <title>Vortex Energy Highlights 2025 Technical Milestones Across Project Portfolio and Announces Adjournment of AGM to February 13, 2026</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vortex-energy-highlights-2025-technical-milestones-across-project-portfolio-and-announces-adjournment-of-agm-to-february-13-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vortex-energy-highlights-2025-technical-milestones-across-project-portfolio-and-announces-adjournment-of-agm-to-february-13-2026</guid>
      <pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
      <description>Technical work completed at Robinsons River and Fire Eye supports next-stage exploration planningVANCOUVER, British Columbia, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to provide a year-in-review summary of technical milestones achieved in 2025, along with a preview of the Company’s exploration plans for 2026. The Company also notes that its annual general meeting (AGM) has been adjourned to February 13, 2026,</description>
    </item>
    <item>
      <title>Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announce-fourth-quarter-and-full-year-2025-financial-results-february-12th</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announce-fourth-quarter-and-full-year-2025-financial-results-february-12th</guid>
      <pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday,</description>
    </item>
  </channel>
</rss>